Carderock Capital Management Inc. Has $7.18 Million Stock Position in STERIS plc (NYSE:STE)

Carderock Capital Management Inc. decreased its position in STERIS plc (NYSE:STE - Free Report) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,588 shares of the medical equipment provider's stock after selling 2,341 shares during the quarter. Carderock Capital Management Inc.'s holdings in STERIS were worth $7,176,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in STE. J.Safra Asset Management Corp boosted its holdings in STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 53 shares during the period. Central Pacific Bank Trust Division bought a new stake in shares of STERIS in the third quarter valued at approximately $28,000. Quent Capital LLC grew its position in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider's stock worth $30,000 after buying an additional 71 shares in the last quarter. Headlands Technologies LLC bought a new position in STERIS during the 1st quarter worth $36,000. Finally, Versant Capital Management Inc raised its holdings in STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 181 shares in the last quarter. Institutional investors own 94.69% of the company's stock.

Insider Buying and Selling

In other STERIS news, Director Christopher S. Holland sold 473 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares of the company's stock, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

STERIS Price Performance

Shares of STE traded down $0.99 during trading hours on Thursday, reaching $225.00. The stock had a trading volume of 648,078 shares, compared to its average volume of 472,977. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. STERIS plc has a 12 month low of $195.47 and a 12 month high of $248.24. The stock has a market capitalization of $22.19 billion, a PE ratio of 56.08 and a beta of 0.84. The company's 50-day moving average is $236.16 and its two-hundred day moving average is $225.91.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The business's revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the firm posted $2.00 earnings per share. Research analysts expect that STERIS plc will post 9.06 EPS for the current year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.01%. This is an increase from STERIS's previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. STERIS's dividend payout ratio (DPR) is 56.58%.

Analysts Set New Price Targets

STE has been the topic of several analyst reports. Stephens reissued an "overweight" rating and set a $260.00 target price on shares of STERIS in a report on Wednesday, August 7th. StockNews.com upgraded shares of STERIS from a "hold" rating to a "buy" rating in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research report on Thursday, August 8th. JMP Securities restated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Finally, KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $246.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.